Emboline Closes $20M Growth Capital
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 hours ago
0mins
Should l Buy TRIN?
Emboline announced it has closed $20M in growth capital from Trinity Capital, a leading international alternative asset manager. Emboline recently completed enrollment in the PROTECT H2H investigational device exemption, or IDE, clinical trial, a prospective randomized study evaluating the Emboliner Embolic Protection System. The funding will support Emboline's upcoming commercial launch activities and continued development of its embolic protection technology platform.The Emboliner Embolic Protection System is designed to provide full cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures. Emboline also holds an extensive intellectual property portfolio related to aortic embolic protection technologies, including full-body embolic filtration and aortic deflection approaches. Results from the completed IDE clinical study will be presented in a Late-Breaking Clinical Trial session on March 29 at the American College of Cardiology Annual Scientific Session in New Orleans, Louisiana. With this financing, Emboline will advance preparations for the commercial introduction of the Emboliner Embolic Protection System while continuing development of additional technologies designed to reduce embolic risk during structural heart interventions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRIN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRIN
Wall Street analysts forecast TRIN stock price to rise
6 Analyst Rating
5 Buy
0 Hold
1 Sell
Moderate Buy
Current: 14.890
Low
13.50
Averages
16.50
High
17.50
Current: 14.890
Low
13.50
Averages
16.50
High
17.50
About TRIN
Trinity Capital Inc. is an internally managed, closed-end, non-diversified management investment company that operates as a business development company. It is a specialty lending company that provides debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its investment objective is to generate current income and capital appreciation through its investments across five vertical markets. It seeks to achieve its investment objective by making investments consisting primarily of term loans and equipment financings and working capital loans, equity and equity-related investments. Its equipment financings involve loans for general or specific use, including acquiring equipment that is secured by the equipment or other assets of the portfolio company. It targets investments in growth-stage companies that are typically private companies, including institutional investor-based companies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emboline Secures $20 Million Growth Capital for Stroke Prevention Technology
- Funding for Commercialization: Emboline has successfully secured $20 million in growth capital, which will support upcoming commercial launch activities and the continued development of its embolic protection technology platform, significantly enhancing its market competitiveness.
- Clinical Trial Progress: Emboline recently completed enrollment in the PROTECT H2H clinical trial, aimed at evaluating the efficacy of the Emboliner® Embolic Protection System, with results to be presented on March 29, 2026, at the American College of Cardiology Annual Scientific Session, potentially providing crucial data for clinical application.
- Innovative Technology Goals: The Emboliner® system is designed to provide comprehensive cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures, which will help reduce the risk of stroke and other embolic complications, thereby enhancing interventional cardiologists' confidence.
- Strategic Partnership: The collaboration with Trinity Capital lays the groundwork for Emboline's commercial launch in the U.S. and Europe, indicating the company's strategic decisions in technology development and market promotion to meet the growing global demand for cardiovascular intervention technologies.
See More
Trinity Capital Commits $20 Million to Emboline for Growth Capital
- Funding Commitment: Trinity Capital has announced a $20 million investment in medical technology company Emboline to support the commercial launch of its Emboliner embolic protection catheter, aimed at reducing the risk of strokes and other complications during minimally invasive heart procedures.
- Clinical Trial Progress: Emboline has recently completed patient enrollment in the PROTECT H2H investigational device exemption clinical trial, which is crucial for generating the data needed for regulatory approval, indicating the company's proactive steps towards product commercialization.
- Manufacturing Expansion: This financing will enable Emboline to scale its manufacturing capabilities, expand its team, and support clinical and regulatory milestones, thereby laying a solid foundation for the successful launch of its product.
- Market Outlook: Trinity Capital's investment not only reflects confidence in Emboline's technology but also indicates a strategic positioning in the medical device sector, which is expected to enhance the company's competitiveness in the rapidly growing healthcare market.
See More
Emboline Secures $20 Million Growth Capital for Stroke Prevention Technology
- Funding for Commercialization: Emboline has successfully secured $20 million in growth capital, which will support its upcoming commercial launch activities and the continued development of its embolic protection technology platform, thereby enhancing its competitive position in the structural heart surgery market.
- Clinical Trial Progress: Emboline recently completed enrollment in the PROTECT H2H clinical trial, aimed at evaluating the efficacy of the Emboliner® Embolic Protection System, with results expected to be presented on March 29, 2026, at the American College of Cardiology Annual Scientific Session, further validating its technology's clinical application potential.
- Innovation Goals: The Emboliner® system is designed to provide comprehensive cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures, thus reducing the risk of stroke and other embolic complications while enhancing interventional cardiologists' confidence in complex procedures.
- Intellectual Property Advantage: Emboline holds an extensive intellectual property portfolio related to aortic embolic protection technologies, including full-body embolic filtration and aortic deflection methods, which lays a solid foundation for future technology development and market expansion.
See More
Trinity Capital Commits $20 Million to Emboline for Growth Capital
- Investment Amount: Trinity Capital has announced a $20 million investment in MedTech company Emboline to support the development of technologies aimed at reducing strokes and other complications during heart procedures, demonstrating strong support for medical innovation.
- Product Innovation: Emboline's Emboliner® Embolic Protection Catheter features a flexible mesh design that captures and removes debris that could lead to strokes while allowing normal blood flow, significantly enhancing the safety of minimally invasive procedures.
- Clinical Trial Progress: Emboline recently completed patient enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial, aiming to generate the necessary clinical data for regulatory approval and commercial launch, marking a significant step towards bringing new technology to market.
- Strategic Partnership: The financing from Trinity Capital will strengthen Emboline's manufacturing capabilities and team expansion, supporting the achievement of clinical and regulatory milestones that will drive the global commercialization of the Emboliner system.
See More
Trinity Capital Commits $35 Million to Neuros Medical for Growth
- Capital Commitment: Trinity Capital announced a $35 million investment in Neuros Medical to support the expansion and commercialization of its Altius Direct Electrical Nerve Stimulation System, aimed at alleviating chronic post-amputation pain, highlighting its commitment to medical innovation.
- Market Expansion: This financing will assist Neuros Medical in scaling the adoption of its therapy and support entry into new markets, thereby enhancing the company's competitiveness in the medical device sector.
- Investment Return Potential: Trinity Capital's investment not only provides essential funding for Neuros Medical but also has the potential to yield significant returns through successful market penetration, improving the overall financial performance of the firm.
- Industry Outlook: With the rising demand for chronic pain management solutions, this investment reflects confidence in medical technology innovation, potentially offering Trinity Capital long-term strategic benefits and market share growth.
See More
Trinity Capital Reports Record Earnings and Strategic Growth in Q4 2025
- Record Investment Income: Trinity Capital achieved a record net investment income of $144 million in 2025, reflecting significant growth across major operating categories and showcasing the company's strong financial performance and market competitiveness.
- Net Asset Value Growth: The company's net asset value increased from $998 million to $1.1 billion in Q4, representing a 10% quarter-over-quarter growth, which underscores successful capital raising and investment strategies that enhance its market position.
- Diversified Portfolio: Trinity Capital's portfolio spans 22 industries with no single borrower exceeding 3.9% of total exposure, demonstrating exceptional risk management capabilities that ensure stability and resilience in uncertain market conditions.
- Robust Investment Pipeline: As of year-end, the company reported $1.2 billion in total unfunded commitments, with 93% of these commitments subject to rigorous ongoing diligence and investment committee approval, indicating a cautious and strategic approach to future investment opportunities.
See More
Emboline Secures $20 Million Growth Capital for Stroke Prevention Technology
- Funding for Commercialization: Emboline has successfully secured $20 million in growth capital, which will support upcoming commercial launch activities and the continued development of its embolic protection technology platform, significantly enhancing its market competitiveness.
- Clinical Trial Progress: Emboline recently completed enrollment in the PROTECT H2H clinical trial, aimed at evaluating the efficacy of the Emboliner® Embolic Protection System, with results to be presented on March 29, 2026, at the American College of Cardiology Annual Scientific Session, potentially providing crucial data for clinical application.
- Innovative Technology Goals: The Emboliner® system is designed to provide comprehensive cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures, which will help reduce the risk of stroke and other embolic complications, thereby enhancing interventional cardiologists' confidence.
- Strategic Partnership: The collaboration with Trinity Capital lays the groundwork for Emboline's commercial launch in the U.S. and Europe, indicating the company's strategic decisions in technology development and market promotion to meet the growing global demand for cardiovascular intervention technologies.
See More
Trinity Capital Commits $20 Million to Emboline for Growth Capital
- Funding Commitment: Trinity Capital has announced a $20 million investment in medical technology company Emboline to support the commercial launch of its Emboliner embolic protection catheter, aimed at reducing the risk of strokes and other complications during minimally invasive heart procedures.
- Clinical Trial Progress: Emboline has recently completed patient enrollment in the PROTECT H2H investigational device exemption clinical trial, which is crucial for generating the data needed for regulatory approval, indicating the company's proactive steps towards product commercialization.
- Manufacturing Expansion: This financing will enable Emboline to scale its manufacturing capabilities, expand its team, and support clinical and regulatory milestones, thereby laying a solid foundation for the successful launch of its product.
- Market Outlook: Trinity Capital's investment not only reflects confidence in Emboline's technology but also indicates a strategic positioning in the medical device sector, which is expected to enhance the company's competitiveness in the rapidly growing healthcare market.
See More
Emboline Secures $20 Million Growth Capital for Stroke Prevention Technology
- Funding for Commercialization: Emboline has successfully secured $20 million in growth capital, which will support its upcoming commercial launch activities and the continued development of its embolic protection technology platform, thereby enhancing its competitive position in the structural heart surgery market.
- Clinical Trial Progress: Emboline recently completed enrollment in the PROTECT H2H clinical trial, aimed at evaluating the efficacy of the Emboliner® Embolic Protection System, with results expected to be presented on March 29, 2026, at the American College of Cardiology Annual Scientific Session, further validating its technology's clinical application potential.
- Innovation Goals: The Emboliner® system is designed to provide comprehensive cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures, thus reducing the risk of stroke and other embolic complications while enhancing interventional cardiologists' confidence in complex procedures.
- Intellectual Property Advantage: Emboline holds an extensive intellectual property portfolio related to aortic embolic protection technologies, including full-body embolic filtration and aortic deflection methods, which lays a solid foundation for future technology development and market expansion.
See More
Trinity Capital Commits $20 Million to Emboline for Growth Capital
- Investment Amount: Trinity Capital has announced a $20 million investment in MedTech company Emboline to support the development of technologies aimed at reducing strokes and other complications during heart procedures, demonstrating strong support for medical innovation.
- Product Innovation: Emboline's Emboliner® Embolic Protection Catheter features a flexible mesh design that captures and removes debris that could lead to strokes while allowing normal blood flow, significantly enhancing the safety of minimally invasive procedures.
- Clinical Trial Progress: Emboline recently completed patient enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial, aiming to generate the necessary clinical data for regulatory approval and commercial launch, marking a significant step towards bringing new technology to market.
- Strategic Partnership: The financing from Trinity Capital will strengthen Emboline's manufacturing capabilities and team expansion, supporting the achievement of clinical and regulatory milestones that will drive the global commercialization of the Emboliner system.
See More
Trinity Capital Commits $35 Million to Neuros Medical for Growth
- Capital Commitment: Trinity Capital announced a $35 million investment in Neuros Medical to support the expansion and commercialization of its Altius Direct Electrical Nerve Stimulation System, aimed at alleviating chronic post-amputation pain, highlighting its commitment to medical innovation.
- Market Expansion: This financing will assist Neuros Medical in scaling the adoption of its therapy and support entry into new markets, thereby enhancing the company's competitiveness in the medical device sector.
- Investment Return Potential: Trinity Capital's investment not only provides essential funding for Neuros Medical but also has the potential to yield significant returns through successful market penetration, improving the overall financial performance of the firm.
- Industry Outlook: With the rising demand for chronic pain management solutions, this investment reflects confidence in medical technology innovation, potentially offering Trinity Capital long-term strategic benefits and market share growth.
See More
Trinity Capital Reports Record Earnings and Strategic Growth in Q4 2025
- Record Investment Income: Trinity Capital achieved a record net investment income of $144 million in 2025, reflecting significant growth across major operating categories and showcasing the company's strong financial performance and market competitiveness.
- Net Asset Value Growth: The company's net asset value increased from $998 million to $1.1 billion in Q4, representing a 10% quarter-over-quarter growth, which underscores successful capital raising and investment strategies that enhance its market position.
- Diversified Portfolio: Trinity Capital's portfolio spans 22 industries with no single borrower exceeding 3.9% of total exposure, demonstrating exceptional risk management capabilities that ensure stability and resilience in uncertain market conditions.
- Robust Investment Pipeline: As of year-end, the company reported $1.2 billion in total unfunded commitments, with 93% of these commitments subject to rigorous ongoing diligence and investment committee approval, indicating a cautious and strategic approach to future investment opportunities.
See More
